|

Fireside Project – Destigmatizing Psychedelics as Healing Agents Through Risk Reduction

ByPsychedelic Spotlight



In this interview, Psychedelic Spotlight’s Swati Sharma and Fireside Co-Founder Hanifa Washington discuss why risk reduction, harm reduction and education are essential components for the growth of psychedelics space.

Fireside Project is a non-profit psychedelic support line helping people trip better while minimizing the risks and fulfilling the potential of people’s psychedelic experiences. They do that by providing compassionate, accessible, and culturally responsive peer support, educating the public, and furthering psychedelic research, while embracing practices that increase equity, power sharing, and belonging within the psychedelic movement.

Fireside Project’s Psychedelic Peer Support Line offers free, confidential peer support by phone and text message to people in the midst of psychedelic experiences, people holding space for others who are in the midst of psychedelic experiences, and people integrating past psychedelic experiences. We do not provide medical care, medical assessment, or psychotherapy.

Timestamps:
0:47 – Fireside’s latest involvement in the psychedelic space | How is the Fireside project a safety net for psychedelic users?
3:50 – The Fireside Project’s origin story
7:05 – Fireside is a resource for people who are under a psychedelic state. How is Fireside involved with the callers after their psychedelic experience?
8:33 – What is The One Village Healing?
13:54 – How can we help destigmatize the use of psychedelics as healing agents?
17:46 – The importance of psychedelic Integration for diverse communities in the psychedelic space

#Fireside #Psychedelics #PsychedelicTrips

source

Similar Posts

  • HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market? [ +Horizons ETF UPDATE]

    Listen, Videos

    Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. This segment is entitled “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” for a reason. The News we present will have major implications Psychedelic Stocks like MindMed (MMED /MMEDF/ MMQ), Compass Pathways (CMPS) and more.

    In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

    1. The Effects of Treating Depression with Psilocybin
    2. Taking Psychedelics in a Ritual Setting
    3. Microdosing study

    After covering the pertinent aspects of these studies, we’ll take a look at Americans’ ability to buy Horizons’ ETF and finally we’ll give you some updates on some decriminalization efforts.

    So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…
    ​
    https://benzinga.grsm.io/thepsychedel
    ​…
    ​Timestamps:
    0:00​ – Intro
    1:24 – Effects of Treating Depression with Psilocybin
    4:03 – Effects of Taking Psychedelics in A Ritual Setting
    7:23 – Exploring the relationship between microdosing, personality & emotional insight
    9:36 – Americans May be able to invest in Horizon’s ETF
    11:42 – Progress on California’s bill that would LEGALIZE Possession of Psychedelics
    12:57 – Massachusetts Approves Psychedelics Decimalization

    General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​​​ ​#psychedelics​​​​ #shroomboom

  • Interview with Awais Spall, Functional Diagnostic Nutrition Practitioner at Integrative Oasis

    Listen, Podcasts

    In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!

  • PSY: The First American Psychedelic ETF [Excerpt]

    Listen, Videos

    Since Last week’s episode was so long, we decided to cut it into pieces so we don’t bore you guys!
    The ETF “seeks to track the BITA Medical Psychedelics, Cannabis, and Ketamine Index, a rules-based index that tracks the performance of companies listed in North American Exchanges that operate business models focused on the legal usage of psychedelics, cannabis, and ketamine for therapeutic purposes.”
    In this excerpt, we cover what the new American psychedelic ETF (PSY:NYSE) is, as well as my thoughts on it!

    Enjoy the mini episode!
    Link:
    https://www.defianceetfs.com/psy/
    https://psychedelicspotlight.com/psy-first-u-s-psychedelic-etf/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Website: https://thepsychedelicinvestor.com/
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifa…

    https://benzinga.grsm.io/thepsychedel…

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PSY #PsychedelicETF

  • Top 5 Psychedelics Milestones In 2021 & What To Expect in 2022 | Science, Funding, Stocks & More

    Listen, Videos

    The psychedelic medicines industry had a revolutionary year in 2021. At the start of the year, there were only a couple of publicly traded companies, but by the end of it, there were dozens. These companies are racing to answer questions such as: Can psychedelics cure depression? Can psychedelic treat anxiety? And, can psychedelics help with mental health?

    Though the answers to these questions have not been proven 100%, after 2021, it does appear more likely than not that the answer to some of these at least, is yes. In this video, we will recap some of the most significant milestones of the psychedelics industry in 2021, and end it with what I am looking forward to in the new year.

    The first big story of 2021 was the IPOs. Though MindMed (MNMD/MMED) and Compass Pathways (CMPS) went public in 2020, companies such as Field Trip Health (FTRP), Numinus Wellness (NUMI), atai Life Sciences (atai), Cybin Corp (CYBN), and dozens of others joined them in 2021. Add to this the launch of ETFs such as the Horizons Psychedelics ETF (PSYK) and the Advisor Shares Psychedelics ETF (PSIL), and 2021 was a huge year for the advent of public companies in the psychedelic medicines space.

    The next big story was uplistings. Not all stock markets are created equal. In order to have the prestigious needed to attract serious money, companies need to be on exchanges such as the Nasdaq, NYSE, and the TSX. In 2021 we saw MindMed, Numinus, Field Trip, Cybin, and more join the big boys league.

    Third, was funding. Psychedelic companies are for the most part biotech companies. In order to get a new drug through the clinical trial process, it takes hundreds of millions of dollars. This year we saw atai, Compass, MindMed, Cybin, and Field Trip, among others, raise over a billion dollars for the industry. This will sustain them for years to come.

    And finally, 2021 saw a few high-profile clinical trials. The most significant was the MAPS Phase 3 clinical trial, which treated PTSD with MDMA-assisted therapy. The results of this trial were earth-shattering. Equally important was the Compass phase 2b trial, treating treatment-resistant depression with Psilocybin.

    Moving into the new year, I am excited to see more clinical trials, and I expect to see mergers in the field.

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy
    @Psychedelic Spotlight

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Psychedelics #MindMed #Psylocybin